For nearly 100 years, Growth Hormone (GH) has been known to impact insulin sensitivity and risk of diabetes. However, the tissue governing the effects of GH signaling on insulin and glucose homeostasis remains unknown. Excess GH reduces fat mass and insulin sensitivity. Conversely, GH insensitivity (GHI) is associated with increased adiposity, augmented insulin sensitivity, and protection from diabetes. Here we induce adipocyte-specific GHI through conditional deletion of Jak2 (JAK2A), an obligate transducer of GH signaling. Similar to whole-body GHI, JAK2A mice had increased adiposity and extreme insulin sensitivity. Loss of adipocyte Jak2 augmented hepatic insulin sensitivity and conferred resistance to diet-induced metabolic stress without overt changes in circulating fatty acids. While GH injections induced hepatic insulin resistance in control mice, the diabetogenic action was absent in JAK2A mice. Adipocyte GH signaling directly impinged on both adipose and hepatic insulin signal transduction. Collectively, our results show that adipose tissue governs the effects of GH on insulin and glucose homeostasis. Further, we show that JAK2 mediates liver insulin sensitivity via an extra-hepatic, adipose tissue-dependent mechanism.
INTRODUCTION
Argentinian Physician Scientist, Bernardo Houssay demonstrated that injection of anterior pituitary extract worsens glycemic control in dogs (1, 2) . In contrast, loss of anterior pituitary function leads to hypoglycemia and increased sensitivity to insulin (3) . Similar results were observed in humans where hypophysectomy ameliorates not only insulin resistance (4-6) but diabetic complications as well (7, 8) . More recently, it has been demonstrated that Growth Hormone (GH) is responsible for much of the pituitary-derived diabetogenic activity (9) . Both lossand gain-of-function studies in humans and rodents support a role for GH in the biology of insulin responsiveness. Specifically, loss of GH receptor (GHR) function in humans and mice is associated with insulin sensitivity and protection against age-related diabetes (10, 11) . Conversely, acromegalic patients with excessive GH secretion and transgenic Gh over-expressing mice have increased mortality and insulin resistance (12) (13) (14) . Collectively, robust physiologic and genetic data support a prominent role for GH signaling in insulin/glucose homeostasis and the etiology of diabetes.
One of the major physiological functions of GH is controlling adipose tissue lipolysis (15, 16) . Recent studies have demonstrated a critical role for insulinmediated suppression of adipocyte lipolysis in the acute inhibition of hepatic gluconeogenesis through reductions in hepatic acetyl-CoA, leading to decreased pyruvate carboxylase activity and flux. Further, macrophage-induced lipolysis was shown to promote increased rates of hepatic gluconeogenesis and fasting hyperglycemia by promoting increased hepatic acetyl CoA content and pyruvate carboxylase activity/flux, as well as increased conversion of glycerol to glucose (17) . Although the ability for GH to promote lipolysis directly is ambiguous, data supporting a causal role for lipolysis in GH-mediated insulin resistance are robust (18, 19) . The role, if any, of lipolytic activity in Growth Hormone Deficiency or GHI-associated augmentation of insulin sensitivity is entirely unknown.
The tissue(s) mediating the effects of GH signaling on insulin and glucose homeostasis has been elusive. Loss of GH signaling in liver through conditional deletion of the GH receptor Ghr (20) , Stat5 (21) , or Jak2 (22) confers lean body mass, fatty liver, and insulin resistance. In stark contrast, mice (23) and humans (10) with global disruption of GHR have increased adiposity and insulin sensitivity.
There are conflicting results regarding skeletal muscle GHI on whole-body insulin sensitivity (24, 25) , none of which phenocopy global GHI. Mice with beta-cell specific disruption of GHR show little effect on fasting insulin levels or insulin content in the pancreas on normal chow (26) . Recently, mice with fat-specific disruption of GHR were described to have increased fat mass but no change in insulin or glucose homeostasis (27) . However, these mice were generated using the Fabp4:Cre which is known to have activity outside of adipose tissue (28) .
In an effort to determine the specific role of adipose tissue in the metabolic activity of GH, we deleted Jak2 from adipocytes using Adiponectin:Cre (here termed JAK2A) (29) . Similar to whole-body GH insensitivity (GHI), and as described earlier the resulting JAK2A mice had increased adiposity. Yet they also had improved whole-body insulin sensitivity. Interestingly, while chronic systemic GH exposure promoted hepatic insulin resistance and lipolysis in control mice, JAK2A animals were refractory to the diabetogenic action of GH. Prominent mechanisms regulating hepatic insulin sensitivity, including reductions in free fatty acids and liver lipid content, failed to account for the insulin sensitizing effects observed in JAK2A mice. Collectively, our work demonstrates that adipose tissue regulates the diabetogenic activity of GH and that a JAK2dependent, adipose-derived factor mediates whole-body insulin sensitivity.
RESULTS
Adipocyte-specific deletion of Jak2 augments adiposity and insulin responsiveness. We disrupted Jak2 specifically in adipocytes using Adiponectin:Cre on an inbred C57BL/6 background (30) . All studies were done using male mice. On normal chow, body weight between control and JAK2A cohorts did not differ ( Figure 1A ). However, JAK2A mice had increases in both absolute and percent body fat ( Figures 1B and 1C Figure   1G . Despite increased adiposity, fasting JAK2A mice were hypoglycemic and trended toward hypoinsulinemia ( Figures 1F and 1G ), implying increased wholebody insulin sensitivity. Consistent with this, the JAK2A cohort was hyperresponsive to insulin during the insulin tolerance test (ITT, Figure 1H ). Thus, despite increased adiposity JAK2A mice have augmented whole-body insulin responsiveness.
Increased hepatic insulin sensitivity and suppression of endogenous
glucose production in JAK2A mice. To definitively determine tissue-specific insulin sensitivity, hyperinsulinemic-euglycemic clamps were performed. There was no difference in clamped plasma insulin levels between groups during the clamp (Supplemental Figure 2B ) and plasma glucose levels were matched at approximately 120 mg/dl ( Figure 2A ). As compared to the control cohort, JAK2A animals required a higher glucose infusion rate (GIR) to maintain euglycemia, confirming augmented whole-body insulin sensitivity ( Figures 2B and 2C ). While basal endogenous glucose production (EGP) was unchanged between groups ( Figure 2D ), clamped JAK2A mice suppressed EGP following insulin infusion nearly 100% and to a much greater extent than control animals ( Figures 2E and   2F ), demonstrating improved hepatic insulin sensitivity. Whole-body glucose disposal ( Figure 2G ) and skeletal muscle-( Figure 2H ) and adipose tissuespecific ( Figure 2I ) glucose uptake did not differ between the cohorts. Therefore, disruption of adipocyte Jak2 confers improved whole-body insulin sensitivity almost entirely via augmented hepatic insulin sensitivity and suppression of hepatic glucose production.
Enhanced insulin-mediated suppression of lipolysis in JAK2A mice. It was recently shown that reductions in adipocyte lipolysis and fatty acids (FA) are major regulators of insulin-mediated suppression of hepatic glucose output (31, 32) . Since GH is a major in vivo regulator of lipolysis and loss of adipocyte Jak2 greatly augmented insulin-induced reductions in EGP, we examined FA levels in the clamped mice. Plasma FA did not statistically differ between the euglycemic control and JAK2A cohorts ( Figure 2J ). Following insulin infusion the JAK2A cohort had lower absolute plasma FA ( Figure 2K ). In addition, insulin-mediated attenuation of isoproterenol-stimulated lipolysis was augmented in JAK2A adipose explants (Supplemental Figure 2H ). However, no difference was appreciated between control and JAK2A mice when expressed as a percent suppression of basal FA ( Figure 2L ). Thus, while reduced lipolysis may contribute to augmented hepatic insulin sensitivity in JAK2A mice, the magnitude of difference between insulin-mediated suppression of EGP and FA (compare JAK2A mice are resistant to diet-induced metabolic derangement. To determine the susceptibility to metabolic stress, we next challenged mice with a high-fat diet (HFD). After ten weeks of HFD, body weight ( Figure 3A ), total ( Figure 3B ) and percent ( Figure 3C ) fat mass, and epididymal fat mass ( Figure   3D ) were unchanged between the control and JAK2A cohorts. The inguinal subcutaneous fat pads weighed more in JAK2A mice ( Figure 3E ). Both fasting blood glucose and insulin were reduced in JAK2A animals ( Figures 3F and 3G ).
During ITT the JAK2A cohort maintained remarkable insulin responsiveness, suggesting whole-body insulin sensitivity was preserved despite HFD ( Fig 3H) .
JAK2A mice maintain exquisite hepatic insulin sensitivity following HFD without changes in FA levels. Hyperinsulinemic-euglycemic clamp experiments
showed conclusively that JAK2A mice retained exquisite insulin sensitivity following HFD. Plasma insulin (Supplemental Figure 2D ) and glucose levels ( Fig.   4A ) were matched in response to a fixed and variable rate infusion, respectively, during the clamp. At steady-state, GIR was nearly doubled in JAK2A animals ( Figure 4C ). Similar to mice on chow, basal EGP was unchanged between the groups ( Figure 4D ). However, while clamped control mice demonstrated hepatic insulin resistance, EGP was completely suppressed following insulin infusion in JAK2A animals, and furthermore appeared negative ( Figures 4E and 4F ).
Negative EGP as measured by tracer dilution during a hyperinsulinemic euglycemic clamp is a well-documented phenomenon that typically occurs in extremely insulin sensitive models with high rates of glucose turnover, likely due to variable mixing of the exogenous 3-3 H-glucose tracer with the endogenous glucose pool (33) . Variable mixing of the 3-3 H-glucose tracer also impacts measures of whole-body glucose disposal, which appeared unchanged between the two cohorts ( Figure 4G ).
However, plasma clearance and tissue accumulation of the non-metabolizable glucose tracer 14 mice are resistant to the metabolic derangements of HFD.
Reduced hepatic triacylglycerol levels do not account for increased insulin sensitivity in chow fed JAK2A mice. Increased tissue lipid deposition strongly correlates with insulin resistance. Therefore, we reasoned that livers of JAK2A mice would have reduced lipid burden. Surprisingly, total levels of hepatic triacylglycerol (TAG) were unaltered between control and JAK2A chow fed cohorts (Supplemental Figure 2E ). Therefore hepatic insulin sensitivity in chowfed JAK2A mice is not associated with reduced total liver lipid content. Following HFD hepatic TAG content was increased in both control and JAK2A animals (Supplemental Figure 2E ). Hepatic TAG levels in HFD-fed JAK2A mice were lower than the control cohort and hence may contribute to preserved insulin sensitivity in JAK2A animals following dietary challenge.
Acute GH treatment induces hepatic insulin resistance which is dependent on adipocyte Jak2. Having established that insulin sensitivity is augmented in the setting of loss-of-function JAK2A mutants, we next determined the role of adipose tissue Jak2 in gain-of-function GH signaling. To this end, control and JAK2A mice were treated with vehicle or supra-physiological doses of recombinant mouse GH daily for five days. GH treatment induced hyperinsulinemia in control and, to a lesser extent, in JAK2A mice (Supplemental Figure 2F ). Following the hyperinsulinemic clamp, plasma insulin levels were equivalent in all groups (Supplemental Figure 2G ). Similar to our previous chowfed clamp study (Figure 2 ), vehicle-injected JAK2A mice required a higher GIR compared to the control cohort ( Figures 5B and 5C ). Systemic GH treatment reduced GIR by ~35% in control animals and by ~19% in JAK2A mice ( Figure   5C ). Basal EGP did not differ between groups ( Figure 5D ). Consistent with our previous study, JAK2A vehicle-treated mice demonstrated augmented EGP suppression following insulin infusion ( Figure 5F ). Conversely, GH treatment significantly reduced insulin-mediated EGP suppression in control animals, confirming the diabetogenic activity of GH ( Figure 5F ). Remarkably, GH injections had no effect on hepatic insulin sensitivity in the JAK2A cohort ( Figures   5E and 5F ). GH treatment diminished whole-body glucose disposal ( Figure 5G) and skeletal muscle glucose uptake ( Figure 5H ) in both control and JAK2A mice.
No differences in adipose tissue glucose uptake were observed ( Figure 5I ).
Thus, only five days of systemic GH exposure induces hepatic insulin resistance in an adipocyte Jak2-dependent manner.
GH promotes adipocyte lipolysis indirectly via JAK2-dependent inhibition
of insulin action. In hyperinsulinemic-euglycemic clamped mice, circulating basal FA levels were unchanged in GH-injected animals ( Figure 5J ). Following insulin infusion, GH-injected control animals failed to suppress plasma FA to the levels of vehicle-treated mice, revealing that GH promoted lipolysis indirectly via inhibitory effects on insulin activity ( Figure 5K ). The ability of GH to antagonize reductions in circulating FA was absent in JAK2A mice ( Figures 5K and 5L) , demonstrating that adipocyte Jak2 transduces the GH signal to interfere with insulin-mediated suppression of lipolysis. This correlated with retention of hepatic insulin sensitivity ( Figure 5E ). Collectively, we conclude that adipose tissue mediates GH-dependent antagonism of insulin's activity in both hepatocytes and adipocytes.
Similar to our earlier clamp experiment (Figure 2 ), neither basal ( Figure 5J ) nor percent suppression of circulating FFA ( Figure 5L ) differed between vehicle treated control and JAK2A animals. Again, the lack of a demonstrable effect on lipolysis occurred concurrent with augmented hepatic insulin sensitivity ( Figure   5E ). A nearly identical pattern was observed for palmitate turnover (Supplemental Figures 2I-2K ). Therefore, hepatic insulin resistance in GH-treated control animals directly correlates with adipocyte Jak2-dependent lipolysis.
Further, the augmented hepatic insulin sensitivity of JAK2A mice may be mediated by a mechanism(s) other than or in addition to inhibition of lipolysis.
GH treatment impairs adipocyte insulin responsiveness.
Since GH attenuated insulin-mediated suppression of lipolysis ( Figure 5K ), we determined the ability of insulin to induce signal transduction in adipose tissue from GH treated mice. Intraperitoneal injection of insulin induced robust insulin receptor (IR) autophosphorylation in control inguinal adipose tissue following a ten-minute exposure (Supplemental Figures 3A and 3B) . Daily GH injections for seven days potently attenuated IR autophosphorylation in control but not JAK2A mice.
Similarly, GH inhibited insulin induced AKT phosphorylation (pAKT) in a JAK2dependent manner (Supplemental Figures 3C and 3D) . Finally, and consistent with a previous report (34) , Pik3r1 (p85α) levels were reduced in JAK2A inguinal adipose tissue.
Adipocyte Jak2 governs hepatic insulin responsiveness. Given that neither liver lipid content nor lipolysis strongly correlated with hepatic insulin sensitivity in mice lacking adipocyte Jak2, we measured hepatic insulin signaling in control and JAK2A cohorts. To this end, we continually exposed mice to recombinant GH for 28 days via mini-osmotic pumps. Subsequently, hepatic insulin responsiveness was assessed via levels of pAKT following injections into the inferior vena cava (i.v.c). Vehicle infused control animals responded robustly to i.v.c. insulin ( Figure 6 ). Conversely, chronic GH exposure strongly abrogated insulin-induced hepatic pAKT, consistent with the diabetogenic action of GH observed during the clamp studies ( Figure 5 ) and previous work (35) . However, GH treatment did not impair insulin-induced pAKT in JAK2A livers, demonstrating that adipocyte JAK2 mediates GH-induced decrease in hepatic insulin responsiveness.
DISCUSSION
Houssay and colleagues first described their landmark studies on extreme insulin sensitivity in hypophysectomized dogs nearly 100 years ago (1) . In 1987, Mayer Davidson lamented that "the mechanism of GH effects on carbohydrate and lipid metabolism is far from clear." Further, "Several studies suggest that the insulin antagonistic effects of GH may be secondary to the increased lipolysis via the glucose-fatty acid cycle. It is disappointing to note that this was the conclusion of the last general review of this area more than 20 years ago, and we have made little progress in substantiating or refuting this hypothesis (36) ." Now, almost 30 years after this review, there is still no clear understanding of the cellular or tissue-level basis underlying the effects of GH on insulin and glucose homeostasis.
Global GHI, in both the physiologic and genetic context, confers insulin sensitivity throughout life. Conversely, acromegalic patients with excessive GH secretion are prone to insulin resistance, risk of diabetes and increased mortality. In fact, it has been proposed that GH hypersecretion may be the cause as much as the consequence of poor diabetic control (37) . These effects have been well documented in dogs, mice, and teleosts (38) Removal of Jak2 from adipose using the same Cre transgene was reported to also induce adiposity with age-related insulin resistance (39) . This is in contrast to our JAK2A mice that, while obese, are exquisitely insulin sensitive, even when challenged with HFD or supra-physiologic amounts of GH. Our work here and previously (29) utilized Adiponectin:Cre which has been shown to be considerably more adipocyte-specific (40 (43) . For instance, we recently published work demonstrating that resolution of hepatic steatosis in hepatocytespecific Jak2 knockout mice (JAK2L) via concomitant deletion of Cd36 is not sufficient to reverse the insulin resistance observed in JAK2L animals (44) .
Others have shown discordance between insulin resistance and tissue lipid deposition, such as in Chanarin-Dorfman Syndrome and genetic forms of hepatic steatosis (45, 46) .
Further, insulin resistance and adiposity fail to correlate in cases of Cowden and
Laron Syndromes (47, 48) . In fact, one of the natural consequences of augmented adipose tissue insulin sensitivity is reduced lipolysis, and hence increased adiposity, as is experienced by patients taking insulin-sensitizing agents such as thiazolidinedione (49) . Here we report that chow-fed JAK2A have increased adiposity, but fail to demonstrate statistical differences in either basal or percent suppression of lipolysis following insulin infusion.
The physiological consequences of adipose tissue insulin sensitivity are glucose uptake and suppression of lipolysis. The former occurs via Akt-regulated GLUT4 transport (50) . However, exactly how insulin suppresses adipose tissue lipolysis is unknown. The major facilitator of insulin-mediated inhibition of lipolysis appears to be PDE3B (51) . Surprisingly, this has been reported to occur in an Akt-independent manner (52) . While GH potently attenuated insulin-induced phosphorylation of Akt (Supplemental Figures 3C and 3D) , no effects on adipose tissue glucose uptake were observed ( Figure 5L ). Therefore, GH seems to selectively affect the anti-lipolytic arm of adipose tissue insulin action. We were unable to detect adipose tissue PDE3B using commercially available antibodies, but a robust inquiry into the potential role of PDE3B in GH-mediated inhibition of insulin-induced suppression of lipolysis in warranted.
In 1963 Philip Randle put forth the notion that FAs may themselves induce insulin resistance (53) . Indeed, increasing levels of circulating FAs highly correlate with insulin resistance (54) . Further, clinical trials testing agents that reduce FAs have shown increased insulin sensitivity outcomes (55) (56) (57) (58) . One of the many actions of insulin is to inhibit adipose tissue lipolysis and hence FA release into the circulation. GH has also been proposed to be a major regulator of adipose tissue lipolysis (15) . Indeed, acromegalic patients have enhanced lipolysis and increased adipose expression of genes that regulate lipolysis (59) . Two independent trials reported that administration of the anti-lipolytic drug acipimox increases insulin sensitivity in GH-treated patients (18, 19) . Collectively, these data support a predominant role for lipolysis in GH-mediated insulin resistance.
Our work here supports these findings. We showed that GH-mediated lipolysis correlates with hepatic insulin resistance and that GH promoted adipose tissue lipolysis through JAK2, but indirectly via perturbation of insulin action. Therefore, the predominant diabetogenic mechanism of GH is likely due to increased adipose tissue lipolysis promoting hepatic insulin resistance. Recently two groups reported that insulin-induced reductions in hepatic glucose output can occur independently of liver insulin signaling (31, 62) . This surprising finding supports older literature showing that insulin inhibits hepatic glucose output indirectly via effects on adipose tissue (63) (64) (65) (66) and suggests that extrahepatic tissue(s) receive insulin signals to mediate hepatic insulin sensitivity. In support of this, selective enhancement of adipocyte insulin sensitivity imparts whole-body glucose homeostasis (67) . Further, transplanting insulin sensitive adipose tissue into insulin resistance animals restores insulin responsiveness (68) (69) (70) . Finally, overt lack of adipose tissue function is sufficient to induce insulin resistance (71) . Therefore adipose tissue may be the dominant regulator of whole-body insulin sensitivity.
Exactly how adipose tissue mediates hepatic insulin sensitivity is unknown, but recent mechanisms have been proposed that include lipolysis (31, 62) . We did not observe consistent differences in adipose tissue lipolysis or liver lipid content in chow-fed, HFD-fed or GH-treated insulin sensitized JAK2A mice. Further, we have not measured consistent or significant changes in classic insulin sensitizing factors such as Adiponectin and Leptin (29) . Therefore, adipocyte JAK2 may mediate insulin sensitivity by a novel mechanism. Previously, it was reported the GH mediates cellular insulin resistance at the level of PI 3-kinase by altering subcellular redistribution of AKT (72) . We found that GH treatment attenuated insulin-induced pAKT in inguinal adipose tissue, but the molecular mechanism remains unknown.
GH has been reported to regulate p85α expression and PI 3-kinase activity in general (34) . Consistently, we observed a reduction in Pik3r1 levels in JAK2A adipose tissue (Supplemental Figure 3E ), but are unable to comment on PI 3kinase activity. When mutated in humans with Cowden Syndrome, the PI 3kinase pathway effector PTEN promotes adiposity coupled to augmented insulin sensitivity (47) .
Here, we report that loss of adipocyte Jak2 is sufficient to impart whole-body insulin sensitivity independent of adiposity and liver lipid content, suggesting the presence of a paracrine regulator of GH diabetogenic activity and highlighting cross talk between adipose and liver. Our results show that acrogmegalyassociated hepatic insulin resistance is a result of attenuated insulin-mediated adipose tissue lipolysis. Finally, we provide evidence to support alternative mechanisms regulating gain-and loss-of-function GH signaling-mediated effects on insulin responsiveness. Isolation of the JAK2-dependent, adipocyte-derived factor(s) mediating whole-body insulin sensitivity may someday lead to new antidiabetic therapeutics.
METHODS

Animals and diets.
The generation of Adiponectin:CRE;Jak2 lox/lox mice was previously described (29) . For our studies reported here, Jak2 lox/lox (73) GH 2.5 mU·kg -1 ·min -1 . Glucose and palmitate turnover were determined as the ratios of the 3-3 H-glucose and U-13 C-palmitate infusion rates to the specific activity or plasma enrichment corrected to the contribution of the infusion rate for plasma glucose and palmitate, respectively, during the last 40 min of the hyperinsulinemic infusion. Calculation of endogenouse glucose production and tissue specific glucose uptake were described previously (74) . For chow studies mice were approximately 16 weeks of age and HFD study mice were agematched to chow studies and fed HFD for 4 weeks prior to clamps. For GH treatment mice received daily vehicle (0.03M NaHCO3, 0.15 NaCl, pH 9.5) or 5 mg/kg recombinant mouse GH (Dr. A. F. Parlow, National Hormone and Peptide Program, UCLA, Torrance, CA) by subcutaneous injection for 5 days prior to clamp.
Mini-osmotic pump studies. Control and JAK2A mice were implanted with 28day Alzet mini-osmotic pumps (Durect Corporation, Cupertino CA) to deliver recombinant mouse GH at a dose of 5 mg/kg/day in GH buffer. At the end of 28 days, mice were fasted overnight (16 hrs) followed by injection with 0.01U insulin via the inferior vena cava. After 5 minutes, the liver was removed and immediately snap frozen in liquid nitrogen. Liver tissue was prepared for gel electrophoresis as previously described (44) . For detection of pAkt and total Akt, liver was homogenized in RIPA buffer (50 mM Tris, 150 mM NaCl, 1% Triton-X100, 1% deoxycholate, 0.1% SDS, 1mM EDTA, pH 7.4) supplemented with protease and phosphatase inhibitors (Thermo Fisher Scientific, Waltham MA).
After incubating on ice for 20 minutes, the homogenate was centrifuged for 20 minutes at 15000 RCF at 4C. The protein concentration of the supernatant was determined using BCA assay (Pierce) and 20 µg of protein used for gel electrophoresis. Antibodies used were anti-phospho-S473-Akt (Cell Signaling Technologies #4060) and total Akt (Cell Si#9272) at a dilution of 1:2000 followed by anti-Rabbit secondary at a dilution of 1:10000. Images were collected using Chemidoc Imager (Bio-Rad, Hercules, CA).
Statistics and graphics. All statistical tests and figures were done using
GraphPad Prism v6.0. For all T tests the P value is included in the figure and is considered significant if less than 0.05.
Study approval.
All animal studies were approved by IACUC at the Universities of California, San Francisco and Pittsburgh, and Yale University.
